Drug Profile
Dostarlimab - GSK
Alternative Names: ANB 011; Dostarlimab-gxly; GSK-4057190; JEMPERLI; Jemperli; TSR 042; WBP 285Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator AnaptysBio
- Developer GSK; Italian Sarcoma Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Endometrial cancer; Solid tumours
- Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase II/III Non-small cell lung cancer
- Phase II Breast cancer; Cervical cancer; Clear cell sarcoma; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Small cell lung cancer; Squamous cell cancer
Most Recent Events
- 26 Mar 2024 GlaxoSmithKline suspends the phase II trial in Solid tumours (Combination therapy, Metastatic disease, Recurrent) in France (IV) (EudraCT2020-002766-14) (NCT04779151)
- 19 Mar 2024 GlaxoSmithKline plans phase-II RUBY-J trial for Endometrial cancer (Combination therapy, Recurrent, Late-stage disease) in Japan (IV, Infusion) in April 2024 (NCT06317311)
- 16 Mar 2024 Efficacy and adverse events data from the phase III RUBY trial in Endometrial cancer released by GSK